Abstract 307P
Background
Lacrimal gland is an exocrine secretory gland located at the upper temporal fossa of the orbit. It is part of the tear-forming apparatus that constitutes an important orbital structure. However, data available about tumors possibly originating in this site are scarce. In this study, we aimed to spotlight on this rare type of malignancy using the using data from American National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program.
Methods
We used SEER*Stat version 8.3.4, Microsoft Excel, as well as SPSS IBM SPSS Statistics for Windows, Version 21.0. In SEER*Stat, we used the (Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying)) database. We included SEER 18 cases that were diagnosed after 2003 (2004+) in which the primary site was identified as (C69.5 – Lacrimal gland). Only cases with malignant behavior, known age, and those in the Research Database were included.
Results
A total of 491 cases were identified with a median age of 63. Females represented the majority of the analyzed cohort (n = 263, 53.6%). Lacrimal gland tumors were most common among the white race (n = 376, 76.6%). Age-adjusted Incidence rate was 0.6 per 1,000,000 with a median survival of 41 months, while 5-year relative survival was 88.4% (CI: 81.9% - 92.6%). The most common pathology of studied cases was Non-Hodgkin lymphoma (n = 254, 51.7%) (Table).Table:
307P Different pathological subtypes for lacrimal gland tumours
Pathological Subtype | N. | % |
---|---|---|
NHL-Mature B-Cell Lymphomas | 254 | 51.7 % |
Squamous Cell Neoplasms | 71 | 14.5 % |
Adenomas &Adenocarcinomas | 64 | 13.0 % |
Malignant Lymphomas, NOS Or Diffuse | 32 | 6.5 % |
Mucoepidermoid Neoplasms | 17 | 3.5 % |
Epithelial Neoplasms, NOS | 10 | 2.0 % |
Nevi Melanomas | 8 | 1.6 % |
Ductal & Lobular Neoplasms | 7 | 1.4 % |
Lymphoid Leukemias (C42.1) | 6 | 1.2 % |
Transitional Cell Papillomas & Carcinomas | 4 | 0.8 % |
Complex Mixed & Stromal Neoplasms | 4 | 0.8 % |
Myomatous Neoplasms | 3 | 0.6 % |
Basal Cell Neoplasms | 2 | 0.4 % |
Complex Epithelial Neoplasms | 2 | 0.4 % |
Plasma Cell Tumors | 2 | 0.4 % |
Unspecified Neoplasms | 1 | 0.2 % |
Cystic, Mucinous & Serous Neoplasms | 1 | 0.2 % |
Fibromatous Neoplasms | 1 | 0.2 % |
Hodgkin Lymphomas | 1 | 0.2 % |
Nhl-Mature T & Nk-Cell Lymphomas | 1 | 0.2 % |
Conclusions
Lacrimal gland tumors are extremely rare with incidence rate of 0.6 per million. These tumors are more likely to occur in old age, females, white race. 5-years relative survival is 88.4% with a median survival of 41 months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers
Presenter: Rajnish Nagarkar
Session: Poster display session
Resources:
Abstract
372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study
Presenter: Yiyu Shen
Session: Poster display session
Resources:
Abstract
373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
Presenter: Aaron Tan
Session: Poster display session
Resources:
Abstract
374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)
Presenter: Nir Peled
Session: Poster display session
Resources:
Abstract
375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
Presenter: Huixin Lin
Session: Poster display session
Resources:
Abstract
376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country
Presenter: Prasanta Dash
Session: Poster display session
Resources:
Abstract
377P - NGS in advanced NSCLC in a developing country: Ready for prime time?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore
Presenter: Chia Wei Lim
Session: Poster display session
Resources:
Abstract
379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India
Presenter: Padmaj Kulkarni
Session: Poster display session
Resources:
Abstract
380P - Ventricular–Subventricular zone involvement: A predictive factor for survival in glioblastoma
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract